SGLT2

SLC5A2

Identifiers

SLC5A2, SGLT2, solute carrier family 5 member 2

External IDs

OMIM: 182381 MGI: 2181411 HomoloGene: 2289 GeneCards: SLC5A2

Targeted by Drug

canagliflozin anhydrous, dapagliflozin, empagliflozin, sergliflozin etabonate

Gene ontology
Molecular function	• low-affinity glucose:sodium symporter activity • symporter activity • transporter activity • glucose:sodium symporter activity
Cellular component	• integral component of membrane • plasma membrane • extracellular exosome • membrane • integral component of plasma membrane
Biological process	• carbohydrate transport • ion transport • glucose transmembrane transport • carbohydrate metabolic process • transport • sodium ion transport • transmembrane transport
Sources:Amigo / QuickGO

Orthologs

Species

Human

Mouse

Entrez


6524


246787

Ensembl


ENSG00000140675


ENSMUSG00000030781

UniProt


P31639


Q923I7

RefSeq (mRNA)


NM_003041


NM_133254

RefSeq (protein)


NP_003032


NP_573517.1 NP_573517

Location (UCSC)

Chr 16: 31.48 – 31.49 Mb

Chr 7: 128.27 – 128.27 Mb

PubMed search

NP_573517.1
NP_573517

The sodium/glucose cotransporter 2 (SGLT2) is a protein that in humans is encoded by the SLC5A2 (solute carrier family 5 (sodium/glucose cotransporter)) gene.

SGLT2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.

SGLT2 inhibitors are called gliflozins and are listed in the article gliflozins. They lead to a reduction in blood glucose levels. Therefore, SGLT2 inhibitors have potential use in the treatment of type II diabetes. Gliflozins enhance glycemic control as well as reduce body weight and systolic and diastolic blood pressure. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic ketoacidosis. Other side effects of gliflozins include increased risk of (generally mild) urinary tract infections, candidal vulvovaginitis.

...
Wikipedia